TECARTUS

by Pill Pals Customer Service | Jun 27, 2025 | News

STN: BL 125703Proper Name: brexucabtagene autoleucelTradename: TECARTUSManufacturer: Kite Pharmaceuticals, Inc.Indication: TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:Adult patients with relapsed or...

Shang Hao Jia, Inc. Issues Allergy Alert on Undeclared Sesame in Danshi Brand Spicy Shredded Tofu

by Pill Pals Customer Service | Jun 27, 2025 | News

Summary Company Announcement Date: June 26, 2025 FDA Publish Date: June 27, 2025 Product Type: Food & Beverages Reason for Announcement: Recall Reason Description Undeclared Sesame Company Name: SHANG HAO JIA, INC Brand Name: Product Description: Company...

YESCARTA Lead Page

by Pill Pals Customer Service | Jun 27, 2025 | News

STN: BL 125643Proper Name: axicabtagene ciloleucelTrade Name: YESCARTAManufacturer: Kite Pharma Inc.Indication: YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:Product InformationSupporting DocumentsJune...

OMUFA Performance Reports

by Pill Pals Customer Service | Jun 27, 2025 | News

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (Pub. L. 116-136) was signed into law. In addition to aiding the COVID-19 response efforts, the CARES Act amended the FD&C Act to include statutory provisions that (1) reform...

ABECMA

by Pill Pals Customer Service | Jun 27, 2025 | News

STN: BLA 125736Proper Name: Idecabtagene VicleucelTradename: ABECMAManufacturer: Celgene Corporation, a Bristol-Myers Squibb CompanyIndications:Treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including...

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS)

by Pill Pals Customer Service | Jun 26, 2025 | News

FDA Safety Communication – June 26, 2025The Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been eliminated because the Food and Drug Administration...